A collaboration between the Institute of Diabetes and Regeneration Research at Helmholtz Zentrum München and Lilly is seeking to improve and accelerate diabetes treatment by researching pancreatic beta cell regeneration.
Focusing on the identification, validation and targeting of novel pathways and molecules for triggering beta cell regeneration, the goal is to develop new therapies that preserve and/or restore mass and functionality of people’s remaining beta cells.
Prof. Heiko Lickert, Director of the Institute of Diabetes and Regeneration Research, said: “We are excited to be working with Lilly. This collaboration is a perfect opportunity to combine the strength of our basic and translational research performed at Helmholtz Zentrum München with Lilly’s expertise in drug discovery and development for diabetes therapy.”
Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
